Metabolic research

After STEP 1: what happened following withdrawal?

The extension study highlights why an end-of-treatment result is not a permanent-outcome guarantee.

Follow-up studyPaper year: 2022Semaglutide

01 / DESIGN

What was studied?

An exploratory extension followed 327 participants from STEP 1 for a year after both study treatment and lifestyle intervention ended.

02 / FINDINGS

What did the researchers report?

Participants previously assigned semaglutide regained about two-thirds of their earlier weight loss on average. Many cardiometabolic measurements moved back toward their starting values.

03 / INTERPRETATION

What are the limits?

The extension involved a subset of the original trial and was exploratory. Because drug treatment and lifestyle support stopped together, it cannot fully isolate their separate effects. It does not prescribe a treatment plan.

Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.

RESEARCH CONTEXT

These are original reading notes on published studies, not product testimonials. Clinical studies used their own pharmaceutical formulations and protocols; their findings do not establish the safety, efficacy or equivalence of materials in our catalog. No personal-use or treatment guidance is provided.

What was studied?

What did the researchers report?

What are the limits?

Continue reading.